Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 9, 2009

Intralytix Wins U.S. Army Contract to Develop Phage-Based Probiotic Against Shigella Infection

  • Intralytix won a U.S. Army Phase I STTR contract to support Phase II development of a bacteriophage-based probiotic dietary supplement that could help reduce the incidence and severity of Shigella infections. Intralytix holds a patent covering the use of phages to reduce bacterial colonization in the GI and nasal tracts.

    The company’s CSO, Alexander Sulakvelidze, Ph.D., admits that using bacteriophages as probiotic/nutraceutical constituents represents a novel concept but says, “we believe this application fits into the definition of a probiotic adopted by the Food and Agriculture Organizaiton of the UN and the WHO.” 

    Intralytix CEO, John Wolszyn, adds that data from the U.S. army-funded project will also enable the company to develop a completely new line of phage-based products for its portfolio. 

    The U.S. Army contract is Intralytix’ third for the development of phage-based products. In June 2009, Intralytix won a contract to develop a bacteriophage-based food safety product for reducing or eliminating pathogenic Salmonella and Shigella contamination of fruits, vegetables, and other food products. In November 2008, the company was awarded a 2009 Army Commercialization Pilot Program (CPP) grant to support the development of a phage-based technology for eliminating or significantly reducing contamination of fruits, vegetables, and red meat by E. coli 0157:H7. Intralytix hopes that this product, EcoShield, would receive regulatory clearance this year.

    Intralytix-marketed phage-based product, ListShield™, was registered in 2008  as an antimicrobial against Listeria monocytogenes contamination. Developed for use in food  processing and handing establishments, ListShield represents the first natural phage-based product used as environmental decontaminant to achieve Environmental Protection Agency clearance, the company claims. The product had previously been granted FDA approval as a food additive on ready-to-eat foods, representing the first and only phage-based food additive approved by the FDA.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »